Apollomics Business Summary

Apollomics Inc. (APLM) is a clinical-stage biopharmaceutical company that generates revenue through strategic licensing, milestone payments, and the prospective commercialization of its oncology pipeline. The company’s business model focuses on developing targeted therapies and immuno-oncology agents for difficult-to-treat cancers, primarily centered on its lead asset, vebreltinib (APL-101). Vebreltinib is a selective c-Met inhibitor in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and other MET-altered solid tumors. Apollomics competes with major pharmaceutical players including Novartis (Tabrecta), Merck KGaA (Tepmetko), and AstraZeneca (Savolitinib). Following a strategic pivot in late 2025, the company operates a lean, high-efficiency model prioritizing MET-amplified indications to differentiate its clinical data within the global oncology market. The company is currently led by Chairman and CEO Hung-Wen (Howard) Chen, who was appointed in September 2025 following a $4.1 million PIPE financing that stabilized the firm. Chen, the founder of Gemtek Technology and former CEO of Polaris Pharmaceuticals, oversees a streamlined executive team including Chief Operating Officer Yi-Kuei (Alex) Chen, a co-founder of Maxpro Ventures, and Chief Financial Officer Peter Lin, formerly of Tanvex Biopharma. While the company was originally co-founded by Dr. Guo-Liang Yu and Dr. Sanjeev Redkar, the current leadership was installed to navigate a period of financial restructuring and maintain the SPARTA clinical program. The board, featuring independent directors like Dr. Moses Chen and Dr. Ya-Chi Huang, is closely aligned with Maxpro Investment Co., Ltd., focusing the firm’s resources on high-priority clinical milestones through 2026.